Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant insulin glargine vs Lantus in Chinese diabetes patients
CTR20180810Phase 3Completed
- Sponsor
- Hefei Tianhui Biotechnology
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine in diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM), sponsored by Hefei Tianhui Biotechnology. Started Aug 2018; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20180810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180810.